Ultragenyx Pharmaceutical Inc. (RARE) 股票分析

公司概述

Ultragenyx Pharmaceutical Inc. operates as a biopharmaceutical company dedicated to the identification, acquisition, development, and commercialization of novel therapeutic products specifically designed for the treatment of rare and ultra-rare genetic diseases across North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. The company functions within the Healthcare sector and the Biotechnology industry, a segment characterized by high research and development expenditures aimed at addressing unmet medical needs for patients with limited treatment options. In terms of scale, Ultragenyx maintains a market capitalization of $2.28 billion while generating trailing twelve-month (TTM) revenue of $673.00 million and employing a workforce of 1,371 individuals. These valuation and revenue figures indicate that the company holds a significant position within the specialized rare disease landscape, possessing substantial cash reserves relative to its current operational output, though its profitability remains negative, which is typical for biotechnology firms in the development and early commercialization phases of their asset portfolios.

财务健康

The company reported total revenue of $673.00 million for the trailing twelve months, yet recorded a net income loss of $575.00 million and an EBITDA loss of $500.00 million; the substantial gap between positive revenue and significant net income losses reveals a cost structure heavily weighted toward research, development, and commercialization expenses that have not yet been fully offset by gross profits. Free cash flow stands at -$251.12 million, indicating that the company is currently consuming cash rather than generating it from operations, which limits immediate financial flexibility for capital expenditures or acquisitions without external financing. The gross margin is reported at -27.6%, the operating margin at -54.7%, and the profit margin at -85.4%, meaning that for every dollar of revenue generated, the company incurs costs that exceed revenue by nearly one-third before taxes and interest, and loses over 85 cents after all expenses are deducted. On the liability side, the company holds $680.00 million in cash and cash equivalents against $1.25 billion in total debt, while the debt-to-equity ratio is listed as N/A, suggesting a capital structure that relies significantly on equity financing or where equity is negligible relative to debt obligations. The current ratio is 2.48, which indicates that the company possesses 2.48 times the liquid assets necessary to cover its short-term liabilities, reflecting a strong position in managing immediate financial obligations despite the overall debt load. Return on Equity is -608.5% and Return on Assets is -22.0%, metrics that reveal that management effectiveness in generating profit from shareholder capital and total assets is currently negative, a common characteristic for biopharmaceutical companies burning cash to bring products to market before achieving break-even status.

估值评估

The trailing twelve-month P/E ratio is N/A due to negative earnings, whereas the forward P/E ratio is 286.12, a stark disparity that implies the market is pricing in significant future earnings growth or restructuring to turn profitable within the next twelve months. The price-to-book ratio is -27.89, a negative figure that indicates the company's market capitalization is valued at a significant discount relative to its book value, often reflecting market concerns about the quality of assets or the inability to generate cash flow from those assets in the short term. Alternative valuation metrics such as the price-to-sales ratio of 3.38 and the EV/EBITDA of -5.62 suggest that investors are valuing the company primarily on its revenue generation potential and pipeline value rather than current profitability or cash flow. The stock has traded between a 52-week high of $42.37 and a 52-week low of $18.29, and while the specific current price is not listed in the provided facts, the forward P/E suggests the market expects a rapid trajectory away from current loss-making metrics. The beta value is 0.25, which indicates that the stock's price volatility is substantially lower than the broader market, suggesting that the asset class may be driven more by specific product pipeline developments than by general market sentiment fluctuations.

Growth & Income

Revenue growth year-over-year is 25.9%, while earnings growth is N/A due to the company reporting a net loss; this divergence implies that the company is expanding its top line rapidly but is not yet converting that revenue expansion into net profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing income to shareholders, the company retains all earnings to reinvest into research, development, and commercialization efforts to achieve future profitability. The overall growth and income profile for Ultragenyx Pharmaceutical Inc. is characterized by aggressive revenue expansion in a niche market with zero current dividend yield and negative earnings, reflecting a high-risk, high-reward investment thesis typical of early-stage biotechnology companies.